Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 5 | 2023 | 107 | 2.430 |
Why?
|
| Endopeptidases | 4 | 2017 | 4 | 1.710 |
Why?
|
| Receptors, Androgen | 2 | 2023 | 14 | 1.530 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2017 | 12 | 1.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2016 | 2 | 1.010 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2023 | 11 | 0.860 |
Why?
|
| Exosome Multienzyme Ribonuclease Complex | 1 | 2023 | 2 | 0.850 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 8 | 0.850 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 14 | 0.840 |
Why?
|
| SUMO-1 Protein | 1 | 2020 | 1 | 0.690 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 14 | 0.680 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2016 | 10 | 0.620 |
Why?
|
| Sumoylation | 4 | 2020 | 5 | 0.550 |
Why?
|
| Mammary Glands, Human | 1 | 2017 | 3 | 0.550 |
Why?
|
| beta Catenin | 1 | 2017 | 8 | 0.540 |
Why?
|
| Cysteine Endopeptidases | 1 | 2017 | 2 | 0.540 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 7 | 0.540 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 21 | 0.530 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 6 | 0.510 |
Why?
|
| Ubiquitins | 1 | 2016 | 1 | 0.500 |
Why?
|
| Chromatin | 1 | 2016 | 7 | 0.500 |
Why?
|
| Proteomics | 1 | 2016 | 23 | 0.490 |
Why?
|
| Humans | 9 | 2023 | 5476 | 0.480 |
Why?
|
| Signal Transduction | 1 | 2017 | 225 | 0.470 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 72 | 0.460 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 17 | 0.420 |
Why?
|
| Female | 4 | 2023 | 2811 | 0.300 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2023 | 1 | 0.220 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 5 | 0.220 |
Why?
|
| Androgens | 1 | 2023 | 10 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 4 | 0.210 |
Why?
|
| Telomere | 1 | 2023 | 5 | 0.210 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2023 | 10 | 0.200 |
Why?
|
| Proteolysis | 1 | 2020 | 7 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 9 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 23 | 0.170 |
Why?
|
| Cell Movement | 1 | 2020 | 64 | 0.160 |
Why?
|
| DNA Repair | 2 | 2016 | 6 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 175 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 1 | 0.140 |
Why?
|
| Protein Stability | 1 | 2017 | 4 | 0.140 |
Why?
|
| Immunoprecipitation | 1 | 2017 | 4 | 0.140 |
Why?
|
| Immunoblotting | 1 | 2017 | 8 | 0.140 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 30 | 0.130 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 50 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2017 | 31 | 0.130 |
Why?
|
| Apoptosis | 1 | 2017 | 55 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 55 | 0.130 |
Why?
|
| Ligases | 1 | 2016 | 1 | 0.130 |
Why?
|
| Polycomb-Group Proteins | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cell Proliferation | 1 | 2017 | 120 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 13 | 0.130 |
Why?
|
| DNA Damage | 1 | 2016 | 11 | 0.130 |
Why?
|
| Genomic Instability | 1 | 2016 | 1 | 0.130 |
Why?
|
| Origin Recognition Complex | 1 | 2016 | 1 | 0.130 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2016 | 1 | 0.130 |
Why?
|
| HEK293 Cells | 1 | 2016 | 32 | 0.130 |
Why?
|
| RNA Interference | 1 | 2016 | 23 | 0.130 |
Why?
|
| Histones | 1 | 2016 | 13 | 0.130 |
Why?
|
| Protein Interaction Mapping | 1 | 2016 | 3 | 0.120 |
Why?
|
| Cell Survival | 1 | 2016 | 57 | 0.120 |
Why?
|
| Genetic Vectors | 1 | 2016 | 7 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 24 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 35 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 52 | 0.120 |
Why?
|
| Protein Binding | 1 | 2016 | 118 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 242 | 0.120 |
Why?
|
| Mice | 1 | 2017 | 719 | 0.110 |
Why?
|
| Animals | 1 | 2017 | 1817 | 0.080 |
Why?
|
| Male | 1 | 2017 | 2765 | 0.070 |
Why?
|
| Drug Inverse Agonism | 1 | 2023 | 2 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 4 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2023 | 24 | 0.050 |
Why?
|
| Liver X Receptors | 1 | 2023 | 18 | 0.050 |
Why?
|
| Homeostasis | 1 | 2023 | 30 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 55 | 0.050 |
Why?
|
| Centromere | 1 | 2016 | 1 | 0.030 |
Why?
|
| G2 Phase | 1 | 2016 | 1 | 0.030 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2016 | 1 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 6 | 0.030 |
Why?
|